Barclays’s Roivant Sciences ROIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $23.8M | Buy |
2,114,867
+605,951
| +40% | +$6.83M | 0.01% | 744 |
|
|
2025
Q1 | $15.2M | Buy |
1,508,916
+939,024
| +165% | +$9.47M | ﹤0.01% | 828 |
|
|
2024
Q4 | $6.74M | Buy |
569,892
+110,371
| +24% | +$1.31M | ﹤0.01% | 1377 |
|
|
2024
Q3 | $5.3M | Buy |
459,521
+75,609
| +20% | +$872K | ﹤0.01% | 1491 |
|
|
2024
Q2 | $4.06M | Sell |
383,912
-63,050
| -14% | -$666K | ﹤0.01% | 1283 |
|
|
2024
Q1 | $4.71M | Buy |
446,962
+52,592
| +13% | +$554K | ﹤0.01% | 1409 |
|
|
2023
Q4 | $4.43M | Buy |
394,370
+24,320
| +7% | +$273K | ﹤0.01% | 1582 |
|
|
2023
Q3 | $4.32M | Sell |
370,050
-20,181
| -5% | -$236K | ﹤0.01% | 1211 |
|
|
2023
Q2 | $3.93M | Buy |
390,231
+158,363
| +68% | +$1.6M | ﹤0.01% | 1345 |
|
|
2023
Q1 | $1.71M | Buy |
231,868
+104,432
| +82% | +$771K | ﹤0.01% | 1748 |
|
|
2022
Q4 | $1.02M | Buy |
127,436
+124,316
| +3,984% | +$993K | ﹤0.01% | 2115 |
|
|
2022
Q3 | $10K | Sell |
3,120
-14,995
| -83% | -$48.1K | ﹤0.01% | 4183 |
|
|
2022
Q2 | $74K | Buy |
18,115
+7,535
| +71% | +$30.8K | ﹤0.01% | 3588 |
|
|
2022
Q1 | $52K | Buy |
+10,580
| New | +$52K | ﹤0.01% | 3994 |
|